SNAP changes, how to slow cognitive decline, topless visitors face fines: Catch up on the day's stories
Here's what else you might have missed during your busy day.
President Donald Trump's megabill makes the largest cuts to food stamps in the program's 86-year history, jeopardizing assistance for more than 42 million people. Large chains like Walmart, Kroger and Dollar General can absorb the impact — but small, independent grocers will be hit hard.
Lifestyle changes can slow the downturn for people in their 60s and 70s, researchers concluded after conducting a large clinical trial. Exercise, diet and socializing all play important roles. This is what you should know before getting started.
A French resort town has started fining people who walk around topless or in their swimsuits anywhere other than on the beach. Some applauded the move, but others suggested there are more important things to worry about, such as crime.
Josh Johnson has played for 14 different teams in the NFL — including the San Francisco 49ers four times, the Baltimore Ravens three times and three other teams twice. That all adds up to a record. It's a life of loneliness and resiliency.
Facing a projected 3.8-foot sea level rise by 2100, this low-lying country is considering drastic action: a multibillion-dollar string of artificial islands that will double as a seawall. See what it could look like.
GET '5 THINGS' IN YOUR INBOX
If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter. 👂 'It's a privilege': Sound recordist Juan Pablo Culasso — a blind conservationist — is preserving the rich audio tapestry of the Colombian wilderness. Through his work, he's helping to make nature accessible for everyone.
A frustrated Trump gives more details on his relationship with Epstein, as the scandal follows him abroad
Trump says there's 'real starvation' in Gaza, contradicting Netanyahu
Shooting at Reno casino leaves multiple people injured, police say
🏖️ Picture perfect: There's no guarantee of hot weather during the summer in Britain, but people go to the beach regardless of the temperatures. Two new photography books explore how different the experience looks compared to other places.
🏎️ Who just became the first Black driver to win a major race on Indianapolis Motor Speedway's 2.5-mile oval?A. Wendell ScottB. Lewis HamiltonC. Bubba WallaceD. Rajah Caruth⬇️ Scroll down for the answer.
👋 We'll see you tomorrow.🧠 Quiz answer: C. Bubba Wallace survived a late rain delay and two overtimes to win the Brickyard 400.📧 Check out all of CNN's newsletters.
Today's edition of 5 Things PM was edited and produced by CNN's Kimberly Richardson and Sarah Hutter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Medscape
26 minutes ago
- Medscape
High Lp(a) Signals Risk Beyond The Coronaries
TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary atherosclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market
Has more than 30 years of experience bringing innovations to market, including one of the world's first drug-eluting coronary stents at Angiotech Pharma Appointment adds world-class capabilities to Tensive as the company approaches pivotal clinical trial milestones Pivotal trial may enable European and U.S. commercialization of Tensive's innovative bioresorbable REGENERA™ and SOFTAG™ devices for breast reconstruction and tissue marking Tensive published positive first impressions from pivotal trial in April, and from first-in-human trial in 2023 Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive's focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe. Dr. Hunter is the founder and CEO of Canary Medical, a medical data company developing implantable sensor technology. Previously, he founded Angiotech Pharmaceuticals, where he led the development of one of the world's first drug-eluting coronary stents, a multi-billion-dollar innovation that transformed interventional cardiology. 'It's a great honor and validation of the medical potential of Tensive's advanced biomaterials that Bill has accepted to lead our board of directors. His track record of successfully guiding pioneering technologies from concept to commercialization is unmatched,' said Sanjay Kakkar, Chief Executive Officer of Tensive. 'Bill's strategic insights and industry perspectives will be crucial advantages as we complete registrational studies and advance our first device into regulatory processes for marketing approval and commercialization in the U.S. and Europe.' Tensive's innovative polymeric bioresorbable scaffolds allow a natural, non-invasive, permanent and safe solution for breast reconstruction during lumpectomy. In addition, they enable precision tissue marking, demarcating the affected area to direct more targeted radiotherapy and improve imaging accuracy during surveillance and follow-up. 'I am truly excited to join Tensive at such a pivotal moment in its journey,' said Bill Hunter, MD, Chairman of the Tensive Board of Directors. 'In addition to being impressed by the leadership, I became convinced that this was an exceptional opportunity after reviewing the recently published interim data from the ongoing pivotal study of REGENERA™, as well as the excellent long-term follow-up data from the first-in-human clinical trial. The enthusiasm expressed by the key opinion leaders involved with the clinical studies further confirmed my impression of the data. I look forward to supporting Sanjay and his experienced team at Tensive as they bring REGENERA™ and SOFTAG™ to the market.' REGENERA™ / SOFTAG™ advanced biomaterial is a bioresorbable implant designed to be placed during lumpectomy surgery. The bioresorbable medical device is gradually absorbed by the body and enables the patient's own tissue to regrow in the area it fills. The result is breast restoration composed of natural tissue that preserves the patient's original breast shape and feel, yet is clearly differentiated from surrounding tissues on imaging, supporting more targeted delivery of radiotherapy and more accurate monitoring for potential recurrence. The biomaterial used in REGENERA™ and SOFTAG™ resembles a sponge with a fine scaffold matrix; its placement during the lumpectomy surgery is a one-step, minimally invasive, rapid and easy-to-adopt procedure. Currently, patients undergoing benign and malignant lumpectomy do not typically receive cosmetic intervention to prevent breast disfigurement, which can be psychologically devastating. Of the 2.1 million lumpectomies performed worldwide each year, 1.9 million are not reconstructed, constituting a sizeable unmet clinical need [1]. Despite the psychological impact of breast disfigurement following lumpectomy, more common cosmetic surgery options are rarely used, because they entail invasive and complex procedures that often fail to achieve the desired outcome. Preliminary data from the first 16 patients in Tensive's ongoing multi-center pivotal trial in 94 patients undergoing malignant lumpectomy were published in Updates in Surgery in April 2025, with investigators writing: 'In conclusion, we are convinced that REGENERA™ could represent a great innovation in breast oncological surgery, representing a possible alternative to volume replacement with faster operative time, faster recovery, less morbidity, and good patient satisfaction [2].' These results followed the publication in Breast Cancer in 2023 of six-month follow-up data from five patients in a first-in-human trial that demonstrated positive outcomes in terms of both safety and performance, leading the clinical investigators who authored the paper to conclude that the data were 'paving the way to an innovative approach with a potential remarkable impact on clinical application of tissue engineering [3].' [1] Analysis based on estimates from the International Society of Aesthetic Plastic Surgery (ISAPS), Breast Cancer Research Foundation (BCRF), the American College of Surgeons (ACS), the World Health Organization (WHO) and Global Market Insights.[2] A.V.E. Lisa et al. Updates in Surgery Apr 2025. Mariniello et al. Breast Cancer 2023. S.r.l. ( is a clinical-stage advanced biomaterials medical device company developing bioresorbable polymeric scaffolds for breast reconstruction and tissue marking. Its patented REGENERA™ biomimetic scaffold is designed to allow regeneration of a patient's own breast tissue to create natural, safe, and lasting reconstruction for patients recovering from lumpectomy or undergoing cosmetic procedures, while its SOFTAG™ precision tissue marking device enables more targeted delivery of radiotherapy and increases the accuracy of surveillance and follow-up. Tensive's mission is to improve clinical outcomes and the quality of life for women worldwide through accessible, innovative, and sustainable solutions. For more information please contact: Tensive Srl Cohesion Bureau media@ Italian and international media & investorsGiovanni Ca' Zorzitensive@ 7 8467 0727 Attachment 20250805 Tensive PR Bill Hunter appointment (final)Error in retrieving data Sign in to access your portfolio Error in retrieving data
